05/12/2025
Redefining approaches to bacterial vaginosis through microbiome research
In her latest publication, Emilia Lahtinen, industrial PhD student at Karolinska Institutet and Gedea Biotech, investigates how treatments can influence the microbiome’s recovery following bacterial vaginosis.
There are always microorganisms, including bacteria and fungi, in and on our bodies, and the va**nal microbiome plays a crucial role in women’s health. In a healthy va**nal microbiome, there is a balance between different bacteria and fungi, depending on factors such as pH-level, medication, hormones, and other things.
A healthy va**nal microbiome is dominated by Lactobacillus species (spp)., which produce lactic acid, hydrogen peroxide, and various antimicrobial compounds. An imbalance in the normal bacterial flora of the va**na is called dysbiosis. This condition is characterized by a reduction in beneficial bacteria, such as Lactobacillus spp., and an overgrowth of potentially harmful bacteria. Dysbiosis is associated with adverse gynecological and obstetric outcomes, such as sexually transmitted infections, pelvic inflammatory disease, and preterm birth. One of the most common consequences of dysbiosis is bacterial vaginosis.
The study, based on Gedea’s CL3 clinical trial, provides new insight into how pHyph supports a favourable microbiome composition without relying on antibiotics.
- It was fascinating to observe the changes in the va**nal microbiome following treatment. The results give us valuable insight into how non-antibiotic treatments like pHyph can support va**nal health and aid in restoring va**nal balance.
pHyph is approved for treatment of bacterial vaginosis, the reduction of its symptoms, and the promotion of a healthy va**nal microbiome. Emilia’s research is important for the further development of pHyph into new therapeutic areas as the prevention of pre-term birth.
https://gedeabiotech.com/product/publications/
